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subjects attending all assessment visits. There was one treat-
ment protocol termination; this subject discontinued HLXL Dan
after week 1 because of a rise in serum transaminase levels.
According to pill counts, overall compliance with study drug was
94 percent. There were no serious adverse events reported.
Overall, there was a signiﬁcant reduction in VAS knee pain that
was evident by week 3 and continued through the end of the
study (see Tables). While there was no signiﬁcant change in the
patient global assessment of disease during the intervention (P
= 0.37), 3 patients reported that they were markedly improved, 2
were moderately improved, and 1 each was slightly improved or
had no change at the ﬁnal visit.
Mean (SE) VAS Knee Pain
Baseline Week 1 Week 3 Week 6 Model F (df) P value
53.5 (5.2) 49.6 (5.2) 42.5 (5.4) 34.3 (5.4) 8.08 (16) 0.002
Mean (SE) Change in VAS Knee Pain
Period Mean (SE) P value
BL to WK 1 -3.9 (3.9) 0.34
BL to WK 3 -11.0 (4.2) 0.02
BL to WK 6 -19.2 (4.2) 0.0003
Conclusions: HLXL Dan at a single daily dose of 5,180 mgs
for six weeks was safe and efﬁcacious in this phase I study in
patients with symptomatic knee OA. A Phase II dose-ranging
placebo-controlled clinical trial of this herbal compound, sup-
ported by a grant from NCCAM, is currently being conducted.
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A COMPARISON OF TWO PHYSICAL THERAPY
PROGRAMS ON FUNCTIONAL CAPACITY,
PROPRIOCEPTION, AND BALANCE IN WOMEN WITH
KNEE OSTEOARTHRITIS
F. Erbahceci, E. Dursun
Hacettepe University, Ankara, Turkey
Purpose: Primary ﬁnding in knee osteoarthritis (OA) is gait
abnormalities. Also, decrease in muscle strength and range
of motion reduced functional capacity, impaired balance and
proprioception together with resultant increased risk of falling
have been reported. The purpose of this study was to investigate
the effects of two physical therapy and rehabilitation programs on
functional capacity, proprioception, and balance in women with
knee OA.
Methods: Forty female patients with knee OA participated in
this study. Patients were randomly and equally divided into two
groups. Group I underwent a physical therapy and rehabilitation
program consisting of hotpack, ultrasound, and proprioceptive
neuromuscular facilitation (PNF) exercises for a total 10 sessions,
5 days per week for 2 weeks. They continued PNF exercises for
3 days per week for additional 4 weeks. Group II underwent
hotpack, ultrasound, and isokinetic exercises for 5 days per
week, for 2 weeks (a total of 10 sessions). Similar to Group
I, they continued isokinetics exercises for 3 days per week for
additional 4 weeks. Patients were evaluated at baseline at the
second and the sixth weeks of treatment. Functional capacity
was evaluated using 15- meter walking distance, time up and go
test and 12- step up and down test. Proprioception was evaluated
using isokinetic dynamometer, and static and dynamic balance
was evaluated using kinesthetic ability trainer.
Results: Functional capacity, proprioception, and balance im-
proved signiﬁcantly in both groups (p<0.05). There were no
signiﬁcant differences between the groups in any of the variables
both at the second and the sixth week of treatment in any of the
groups (p>0.05).
Conclusions: Two different physical therapy and rehabilitation
programs had favorable effects on functional capacity, proprio-
ception and balance in women with knee OA. Therefore, both
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Purpose: To compare the pharmacokinetics of glucosamine
following treatment with glucosamine sulphate or glucosamine
hydrochloride in a large animal model and to compare the syn-
ovial ﬂuid levels attained following the administration of each
formulation at clinically relevant doses.
Methods: Eight adult female horses were used. After an
overnight fast, crystalline glucosamine sulphate (Dona®) or glu-
cosamine hydrochloride were administered at a dose of 20 mg/kg
by either intravenous (IV) injection or nasogastric (NG) intuba-
tion. Plasma samples were collected before dosing and at 5,
15, 30, 60, 120, 360, 480 and 720 minutes after dosing. Syn-
ovial ﬂuid samples were collected from the radio-carpal joints
within 48 hours before dosing and at 1, 6 and 12 hours post
dosing. Glucosamine was measured in both plasma and syn-
ovial ﬂuid by Liquid Chromatography Electrospray Tandem Mass
Spectrometry (LC-ESI/MS/MS).
Results: Endogenous plasma and synovial glucosamine con-
centrations were not signiﬁcantly different and ranged between
< 10 ng/mL (LOQ) and 39.1 ng/mL. Following IV injection of
either compound, plasma concentrations reached ∼ 50 µg/mL
and declined in a similar multi-exponential fashion. After NG ad-
ministration, plasma concentrations attained ∼ 1 µg/mL for both
types of glucosamine with no signiﬁcant difference in attained
median maximal plasma concentrations. The median elimination
half-life of glucosamine after oral glucosamine sulphate admin-
istration was 4.0 hours and 3.0 hours after oral glucosamine
hydrochloride administration. The median oral bioavailability was
marginally but not signiﬁcantly higher for glucosamine sulphate
than for glucosamine hydrochloride and reached 9.4 % and 6.1 %
respectively. The AUC0-12hr and the AUC0-inf were signiﬁcantly
higher and the relative clearance was signiﬁcantly lower after
oral glucosamine sulphate treatment compared to glucosamine
hydrochloride treatment. The median maximal synovial ﬂuid con-
centrations were signiﬁcantly higher following oral treatment with
glucosamine sulphate (158.3 ng/mL) compared to oral adminis-
tration of glucosamine hydrochloride (88.9 ng/mL). The difference
in synovial ﬂuid concentrations attained following NG adminis-
tration was statistically signiﬁcant at 1 and 6 hours, but not at
12 hours post treatment. Twelve hours after oral treatment with
glucosamine hydrochloride, plasma and synovial glucosamine
levels had returned to baseline levels. Following oral adminis-
tration of glucosamine sulphate, glucosamine levels in plasma
and the synovial ﬂuid were still signiﬁcantly higher than base-
line twelve hours post-treatment. The difference in synovial ﬂuid
glucosamine concentrations attained between treatment groups
was not statistically signiﬁcant following IV treatment.
Conclusions: Following oral administration of a clinically rec-
ommended dose of glucosamine sulphate (Dona®), signiﬁcantly
higher synovial ﬂuid concentrations of glucosamine are attained,
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when compared to an equivalent dose of glucosamine hydrochlo-
ride. Whether this difference in synovial levels of glucosamine
attained is translated into a therapeutic effect on the joint tissues
remains to be elucidated.
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REQUIREMENT FOR TOTAL ARTICULAR REPLACEMENT
AFTER DIACEREIN TREATMENT IN HIP
OSTEOARTHRITIS: A 5 YEARS FOLLOW-UP OF THE 3
YEARS PLACEBO-CONTROLLEDECHODIAH TRIAL
M. Dougados1, L. Gossec1, M. Nguyen1, L. Berdah2,
B. Mazieres3, E. Vignon4, M. Lequesne5
1René descartes University, Paris, France; 2Negma
Laboratories, Paris, France; 3Paul Sabatier University, Toulouse,
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Purpose: Evaluation of disease modifying osteoarthritis drug
(DMOADs) in hip osteoarthritis (OA) is based on effects on both
symptoms and structure. Such a beneﬁcial effect might result
in a subsequent hard end-point (e.g. requirement to total hip
replacement (THR).
The objective of this study was to evaluate the long term (5 years)
effect on requirement for THR of a 3 years intake of diacerein in
comparison to placebo in hip OA.
Methods: Two periods: a) 3 years controlled trial evaluating
the effects on the structure and the symptoms of 50 mg diac-
erein b.i.d. versus placebo (Dougados M, et al. Evaluation of
the structure modifying effects of diacerein in hip osteoarthri-
tis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis
Rheum 2001;44:2539-47); b) 5 years follow-up via an annual
phone call contact. Collected data: at baseline demographics
and OA characteristics (femoral head migration, radiological joint
space width [JSW]). During the 3 years of the therapeutical trial
and the 5 years of follow-up: requirement to THR. Analysis: pri-
mary analysis: percentage of patients requiring THR with regard
to the treatment group in patients completing the 3 years placebo
controlled trial (clinical trial completers) using life table analysis
technique and log-rank test; secondary analyses: identical end-
points and statistical analysis but a) in the whole population
entering the trial at year 0, b) in the sub-group of patients with
supero-lateral and concentric femoral head migration (excluding
the patients with a supero-medial femoral head migration) and a
baseline (year 0) JSW of at least 1.5 mm as suggested by the
Barcelona consensus meeting (Altman RD, et al. Measurement
of structural progression in osteoarthritis of the hip: the Barcelona
consensus group. Osteoarthritis Cartilage 2004;12:515-24.).
Results: Of the 507 included patients (255 and 252 in the
diacerein and placebo groups, respectively), 262 completed the
3 years of the therapeutical trial (127 in the diacerein group).
For these patients, a THR was required during the subsequent
5 years in 40% after diacerein intake versus 43% after placebo
(p=0.60). In the whole group of patients entering the trial, a THR
was performed at the end of the 8 years follow-up period in 56%
whatever the initial treatment group (p=0.94). In the sub-group
of 283 patients fulﬁlling the criteria proposed by the Barcelona
consensus group at entry (149 in the diacerein group), a THR
was performed at the end of the 8 years follow-up period in 49%
after diacerein intake vs 55% after placebo, (p=0.50). In this sub-
group, 157 patients (81 in the diacerein group) completed the 3
years of the therapeutical trial. For these patients, a THR was
required during the subsequent 5 years in 32% after diacerein
intake vs 44% after placebo (p=0.21).
Conclusions: This study failed to demonstrate a statistical sig-
niﬁcant difference between the two treatment groups with regard
to the requirement to THR after a 3 years intake of diacerein in
the a priori deﬁned primary analysis. However, the trend in favor
of diacerein in different clinically relevant sub-populations sug-
gests that a 3 years intake of diacerein might have a subsequent
long term beneﬁcial effect in a sub-group of hip OA patients.
Such ﬁndings should be evaluated in further clinical trials.
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PHARMACOKINETICS OF GLUCOSAMINE IN MAN
AFTER ORAL ADMINISTRATION OF CRYSTALLINE
GLUCOSAMINE SULFATE OR GLUCOSAMINE
HYDROCHLORIDE ALONE OR IN COMBINATION WITH
CHONDROITIN SULFATE
S. Persiani1, L.C. Rovati1, E. Pastorini2, M. Locatelli2,
G. Giacovelli1, D. Paganini1, A. Roda2
1Rottapharm, Monza, Italy; 2Dept. of Pharmaceutical Sciences,
University of Bologna, School of Pharmacy, Bologna, Italy
Purpose: Crystalline glucosamine sulfate and glucosamine hy-
drochloride alone or in combination with chondroitin sulfate have
been evaluated as a treatment for knee pain from osteoarthri-
tis (OA) in two recent studies of 6-month duration. The NIH-
sponsored GAIT study did not show any effect of treatment
with 500 mg glucosamine hydrochloride three times daily (t.i.d.)
alone or in combination with 400 mg of chondroitin sulfate t.i.d.
Conversely, the GUIDE trial indicated that, at the dose of 1500
mg once-a-day, crystalline glucosamine sulfate soluble powder
provided a signiﬁcant symptomatic effect, thus conﬁrming pre-
vious long-term study observations. The pharmacokinetics of
crystalline glucosamine sulfate 1500 mg once-a-day were re-
cently investigated and showed glucosamine peak plasma levels
in the 10 µM range. These levels were effective in vitro in in-
hibiting IL-1-induced gene expression, currently regarded as the
putative mechanism of action of glucosamine in OA. Conversely,
preliminary studies of the pharmacokinetics of glucosamine after
administration of the glucosamine hydrochloride capsule formu-
lation used in GAIT, suggested that the peak levels might be
much lower. The aim of the present study was therefore to
investigate in a direct comparative study, the relative bioavail-
ability of glucosamine following repeated oral administration of
the two glucosamine salt formulations and dose regimens, or
of the glucosamine hydrochloride/chondroitin sulfate combina-
tion, to assess if differences in exposure to the active ingredient
and especially in peak plasma levels, might provide a possible
explanation for the contrasting clinical results.
Methods: Twelve healthy volunteers (5 males and 7 females)
received three consecutive once-daily oral administrations of
crystalline glucosamine sulfate soluble powder at the dose of
1500 mg, or glucosamine hydrochloride capsules at the dose
of 500 mg t.i.d. for thee consecutive days either alone or in
combination with chondroitin sulfate 400 mg t.i.d. in an open,
randomised, cross-over fashion. Glucosamine was determined
at steady state in plasma collected up to 48 h after the last dose
by a validated LC-MS/MS method.
Results: Glucosamine was bioavailable after administration of
the three products. After crystalline glucosamine sulfate 1500 mg
once-daily, peak concentrations (Css,max) and extent of exposure
(AUCss) averaged 9.1±6.3 µM and 76.5±23.0 µM.h, respec-
tively. Signiﬁcantly (p≤0.005) lower plasma concentrations were
determined after the administration of 500 mg glucosamine hy-
drochloride alone (Css,max and AUCss averaged 4.5±1.8 µM and
21.4±7.6 µM.h, respectively) or in combination with 400 mg of
chondroitin sulfate (Css,max and AUCss averaged 3.3±1.0 µM and
13.8±5.4 µM.h, respectively).
Conclusions: Administration of glucosamine hydrochloride at
the dose of 500 mg t.i.d might produce a similar extent of
systemic exposure to glucosamine throughout the day, but at
signiﬁcantly lower (less than a half) peak plasma concentra-
tions compared to 1500 mg of crystalline glucosamine sulfate
